Skip to main content
. 2020 Oct 9;12(11):e12305. doi: 10.15252/emmm.202012305

Figure 4. ILC2s and Tregs contributed to IL‐33‐mediated islet protection in vivo .

Figure 4

  • A
    Streptozotocin‐induced diabetic DEREG C57BL/6 mice were treated with mouse recombinant IL‐33 daily for 5 consecutive days, as well as diphtheria toxin (DT), PC61 or DT+PC61 on days −4 and sletallogr1 prior to and on day 2 post‐islet transplantation. Mice were sacrificed at day 80 post‐islet transplantation or at the day when grafts were considered rejected.
  • B, C
    Proportion of CD4+Foxp+Tregs (B) and Lin-GATA‐3+ILC2s (C) from the spleens and kidneys of islet transplant mice receiving vehicle, IL‐33, IL‐33/DT, IL‐33/PC61, or IL‐33/DT/PC61 at day 5 post‐islet transplantation. Data shown are the mean ± SEM (n = 4–5 per group), and a one‐way ANOVA was performed; NS: non‐significant, ***P < 0.001.
  • D
    Islet graft survival of five groups of mice was assessed by monitoring blood glucose and calculated using the Kaplan–Meier method. Cumulative data from two independent experiments are shown. Statistical analysis was performed with a log‐rank test. *P < 0.05, **P < 0.01.
  • E
    Data are shown as blood glucose measurement in islet transplant mice treated with IL-33/DT, IL‐33/PC61, or IL‐33/DT/PC61. The horizontal black line indicates a BGL of 16 mmol/l, the threshold for rejection. Each line represents one mouse.